	US 11,787,842 B2
	Tuberculosis compositions and methods of using the same
Ravi Anantha, New York, NY (US); Nathalie Cadieux, New York, NY (US); Thomas G. Evans, New York, NY (US); Michele Stone, New York, NY (US); and Barry Walker, New York, NY (US)
Assigned to International AIDS Vaccine Initiative, Inc., New York, NY (US)
Filed by International AIDS Vaccine Initiative, Inc., New York, NY (US)
Filed on Apr. 21, 2021, as Appl. No. 17/236,409.
Application 17/236,409 is a continuation of application No. 16/289,919, filed on Mar. 1, 2019, granted, now 11,014,969.
Application 16/289,919 is a continuation of application No. 14/313,694, filed on Jun. 24, 2014, granted, now 10,266,574, issued on Apr. 23, 2019.
Claims priority of provisional application 61/838,872, filed on Jun. 25, 2013.
Prior Publication US 2021/0371474 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/35 (2006.01); A61K 39/04 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/35 (2013.01) [A61K 39/04 (2013.01); A61K 2039/523 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01)]

14 Claims

1. A composition comprising at least five Mycobacterium tuberculosis (Mtb) antigens, wherein the Mtb antigens comprise:

at least two acute Mtb antigens comprising a first acute Mtb antigen linked to a second acute Mtb antigen,

at least one latent Mtb antigen, and

at least two resuscitation Mtb antigens comprising a first resuscitation Mtb antigen linked to a second resuscitation Mtb antigen.